Compare EOG Resources Inc (EOG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Organon & Co. Common Stock — how do they compare? EOG Resources Inc trades at $155 (market cap $80.34B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: EOG Resources Inc is far larger — about 22.2× Organon & Co. Common Stock's market cap, and EOG Resources Inc pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Organon & Co. Common Stock for 0 Days on average.
| EOG | OGN | |
|---|---|---|
Market Cap | $80.34B | $3.62B |
Volume | 2,309,813 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $154.19 | $13.81 |
52-Week Low | $101.78 | $5.70 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $83.69B | $11.04B |
Dividend Yield | 2.66% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $154.19, up 2.45% today, with a bullish technical outlook and strong fundamentals. The stock has beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Valuation ratios are attractive, including a P/E of 11.92 and EV/EBITDA of 6.02. Recent news highlights robust operational execution and a CFO transition.
The outlook remains positive, supported by analyst consensus of a $165 price target and 59% buy ratings. Key risks include oil price volatility and capital expenditure trends. Upside potential hinges on sustained earnings growth and disciplined capital allocation amid energy market fluctuations.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
